Simrén, Joel
Brum, Wagner S.
Ashton, Nicholas J.
Benedet, Andrea L.
Karikari, Thomas K.
Kvartsberg, Hlin
Sjons, Emma
Lussier, Firoza Z.
Chamoun, Mira
Stevenson, Jenna
Hopewell, Robert
Pallen, Vanessa
Ye, Keqiang
Pascoal, Tharick A.
Zetterberg, Henrik
Rosa-Neto, Pedro
Blennow, Kaj
Funding for this research was provided by:
University of Gothenburg
Article History
Received: 21 March 2022
Accepted: 14 December 2022
First Online: 22 December 2022
Declarations
:
: The Douglas Institute Research Ethics Board (Protocols: IUSMD 16-60 and 16-61) approved the study, and written informed consent was obtained from all participants.
: NA.
: Dr. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB reported personal fees from Abcam, Axon, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens outside the submitted work and being cofounder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program. All other authors report no disclosures.